ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. All of ACADIA's product candidates emanate from internal discoveries. We believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. ACADIA’s history is rooted in science and strong leadership in CNS research. Our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. Since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders.
ACADIA is headquartered in San Diego. The city represents the second largest biotechnology industry cluster in the United States, home to over 400 companies, as well as the Salk Institute for Biological Studies and the Scripps Research Institute.
ACADIA Pharmaceuticals was founded in 1993 and is headquartered in San Diego, US
ACADIA Pharmaceuticals Office Locations
ACADIA Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
300 3611 Valley Centre Dr
ACADIA Pharmaceuticals Data and Metrics
ACADIA Pharmaceuticals Financial Metrics
ACADIA Pharmaceuticals's revenue was reported to be $17.3 m in FY, 2016 which is a 28311% increase from the previous period.
$, USD
Revenue (FY, 2016) | 17.3 m |
Revenue growth (FY, 2015 - FY, 2016), % | 28311% |
Gross profit (FY, 2016) | 14.3 m |
Gross profit margin (FY, 2016), % | 82% |
Net income (FY, 2016) | (271.4 m) |
EBIT (FY, 2016) | (272.8 m) |
Market capitalization (23-Jun-2017) | 3.6 b |
Closing share price (23-Jun-2017) | 28.7 |
Cash (31-Dec-2016) | 163.6 m |
ACADIA Pharmaceuticals's current market capitalization is $3.6 b.
- Source: SEC Filings
| $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 1.1 m | 120 k | 61 k | 17.3 m |
Revenue growth, % | (90%) | (49%) | 28311% | |
Cost of goods sold | 3.1 m | |||
Gross profit | 14.3 m | |||
Gross profit Margin, % | 82% | |||
R&D expense | 26.7 m | 60.6 m | 73.9 m | 99.3 m |
General and administrative expense | 12.7 m | 32.7 m | 88.3 m | 186.5 m |
Operating expense total | 39.4 m | 93.4 m | 164.7 m | 290.1 m |
EBIT | (38.3 m) | (93.2 m) | (164.6 m) | (272.8 m) |
EBIT margin, % | (3345%) | (77692%) | (269856%) | (1574%) |
Interest income | 349 k | 755 k | 499 k | 2.8 m |
Pre tax profit | (37.9 m) | (92.5 m) | (164.1 m) | (270.1 m) |
Income tax expense | 330 k | 1.3 m | ||
Net Income | (37.9 m) | (92.5 m) | (164.4 m) | (271.4 m) |
- Source: SEC Filings
| $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 11.7 m | 61.9 m | 102.1 m | 163.6 m |
Accounts Receivable | 5.9 m | |||
Inventories | 1.2 m | 2.2 m | 7.5 m | |
Current Assets | 188.4 m | 324.6 m | 219 m | 547.9 m |
PP&E | 579 k | 553 k | 2.2 m | 3.1 m |
Total Assets | 189.1 m | 325.5 m | 221.9 m | 561.2 m |
Accounts Payable | 372 k | 2 m | 1.7 m | 3.9 m |
Current Liabilities | 7 m | 15.8 m | 21.9 m | 42.6 m |
Additional Paid-in Capital | 587.7 m | 807.6 m | 862.3 m | 1.5 b |
Retained Earnings | (405.7 m) | (498.1 m) | (662.6 m) | (934 m) |
Total Equity | 182.1 m | 309.5 m | 199.8 m | 518.4 m |
Financial Leverage | 1 x | 1.1 x | 1.1 x | 1.1 x |
| $, USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | (92.5 m) | (164.4 m) | (271.4 m) |
Depreciation and Amortization | 206 k | 647 k | 1.8 m |
Accounts Receivable | (5.9 m) | ||
Inventories | 652 k | (804 k) | (4.7 m) |
Accounts Payable | 1.6 m | (344 k) | 2.2 m |
Cash From Operating Activities | (66.4 m) | (121.8 m) | (210.4 m) |
Purchases of PP&E | (180 k) | (2.1 m) | (1.5 m) |
Cash From Investing Activities | (87.3 m) | 147.6 m | (261.9 m) |
Long-term Borrowings | (32 k) | ||
Cash From Financing Activities | 203.9 m | 14.5 m | 533.8 m |
Income Taxes Paid | 415 k | 365 k |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.1 x |
